IP17-APOLLO - A randomised control trial of hormone therapy prior to focal therapy versus focal therapy alone in men with localised prostate cancer.

IP16-SCOPE - An evaluation of outcomes of men with low or intermediate risk prostate cancer managed with active surveillance over the past 15 years.

IP14-FOCUS - Assessing the role of contrast-enhanced ultrasound in optimising the delivery and effectiveness of focal therapy for prostate cancer.

A national study evaluating new approaches to prostate cancer screening, aiming to find the most effective and acceptable method for early detection.

IP11 - Aiming to understand how the primary tumour in the prostate, and the treatment of this, can affect secondary tumours at other sites.

IP10 - A randomised control trial of PSMA PET imaging in directing treatment for high risk prostate cancer.

IP9 - A randomised control trial of regular MRI scans compared to standard of care in patients with prostate cancer managed using active surveillance.

IP8 - Assessing the accuracy of digital fluorescence confocal microscopy for assessment of surgical margins in radical prostatectomy specimens.

IP7 - An evaluation of Biparametric MRI and Image Fusion targeted biopsy.

IP6 - A validation study of a new AI tool that is reported to be able to detect and rule out prostate cancer on high resolution scanned pathology slides.

IP5 - Aimed at understanding men’s preferences and decision making in regard to current and new treatments for advanced prostate cancer.

IP4 - A comparison study between whole gland and focal treatment in new localised prostate cancer, with the aim to directly compare effectiveness.

IP3 - A pilot study exploring a trial design (cohort-multiple RCT) that has not previously been utilised in the field of prostate cancer research.

IP2 - Investigating treating the prostate and other cancer deposits in men with already advanced cancer in a bid to halt further spread.

IP1 - Aimed at finding and trialing an imaging technique, like mammograms for breast cancer, that could be offered as a screening test for prostate cancer.